Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
about
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationIncidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomibChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological MalignancyThe systemic cytokine environment is permanently altered in multiple myelomaPreemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaRisk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.Update on the optimal use of bortezomib in the treatment of multiple myelomaAdverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myelomaThe risk factors for herpes zoster in bortezomib treatment in patients with multiple myelomaInteraction between IL-6 and TNF-α genotypes associated with bacteremia in multiple myeloma patients submitted to autologous stem cell transplantation (ASCT).Immunoglobulin replacement therapy in secondary hypogammaglobulinemiaIntractable hiccups due to herpetic esophagitis in an immunocompromised patientMultiple myeloma and infections: a population-based study on 9253 multiple myeloma patients.Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy.Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.Non-osseous incidental findings in low-dose whole-body CT in patients with multiple myeloma.Risk of invasive Haemophilus influenzae type b (Hib) disease in adults with secondary immunodeficiency in the post-Hib vaccine eraMonoclonal gammopathy of undetermined significance and risk of infections: a population-based studyImpact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell TransplantationLenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis.Use of antifungal drugs in hematologyAnalysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.Ophthalmic manifestations of herpes zoster virus in patients with multiple myeloma following bone marrow transplantation.Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.Impact of pretransplant donor and recipient cytomegalovirus serostatus on outcome for multiple myeloma patients undergoing reduced intensity conditioning allogeneic stem cell transplantation.Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.High prevalence of cardiovascular and respiratory abnormalities in advanced, intensively treated (transplanted) myeloma: The case for 'late effects' screening and preventive strategies.Common community-acquired infections and subsequent risk of multiple myeloma: a population-based study.Challenges in microbiological diagnosis of invasive Aspergillus infections.Novel treatment regimens for Waldenström's macroglobulinemia.Bortezomib for previously untreated multiple myeloma.Immune alterations in untreated and treated multiple myeloma.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolDiagnosis and therapy of multiple myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.International Myeloma Working Group recommendations for global myeloma care.Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma
P2860
Q27002668-754A0C4B-F607-47EB-9548-D74345DB8172Q27014143-E7EB502A-47F9-4396-A1FF-C9CD83680898Q28080304-A8E96EE9-D686-4C0F-BB0E-668BBA8E0393Q28489028-7CCB1868-024F-4161-9253-6F34EC42236AQ33407012-5ED92AA3-6BFB-4B78-9D07-81F13C3EF00CQ33413142-33B17331-B102-4087-81A2-C1CE2233C9E5Q33434435-659AFE01-84C6-4026-A1A2-82319E374D27Q33440007-E1AF3EFD-68B4-4A2B-8071-29DFAD8ED379Q33441845-B5DCDCC0-1B4D-448E-BC0D-B4558B4FFF4BQ33562719-A8CA014D-16E4-4F61-9050-79ABB8E8012AQ34316960-860CC6C4-DD32-4F03-A22D-CA944E8D8095Q34436188-3086BB6A-46CF-434D-91B1-525454378564Q34652046-A65C1137-D209-4330-A5D8-79CE95F936A2Q34676877-46868262-D202-4ABF-A16B-DC82E970967CQ34798105-F34BBDC5-D8BF-4535-AF30-033F273DBC6EQ34900554-FBD76359-ADA8-43D0-B193-E98318B07685Q35066433-F4E61D98-A8EE-46B1-8542-41610309D3B3Q35676662-F8A2D607-D252-4FD5-A3F0-3014B9E4A8CBQ35940648-82FD3242-1460-489B-A8D6-AA98C5A7BF1FQ36006375-2FF39A73-F1CB-4817-90C3-85C85A45BC6DQ36055170-8D2800C0-AC98-421B-B680-4C1204EED7F2Q36351120-2BDEF0AD-3AEC-4CC3-909F-C58DF6B8FBEEQ36364856-4316C12E-67E2-47E6-A15E-01244CD43316Q36498366-ED12B5BB-663D-49C1-9B23-739B76BD2C89Q36703679-CF84BBC5-825E-44E3-AD37-862749EFE667Q36764389-A259E0AE-3427-4FA8-88E9-B1788BB9E255Q36806619-7A6C88E7-A917-4AE4-BCB7-27CCE347F8CCQ36826198-460CC422-97D1-443F-8DD2-679CE6453348Q36897035-EBD8E021-84A6-4E94-8F93-9779ACB6BC26Q37107428-913EA93A-D026-44D6-B1F1-96CA87E8546EQ37625852-2DFD82BE-51CF-481A-BA13-BC6E310FB667Q37659157-25CB5952-F5A9-4BBE-A629-19B48965A9BAQ37810101-016B213E-1DC2-488F-B22B-43BA896B1FB4Q37908155-4E364F50-B290-48FA-AC52-6AB56282B1DCQ37920966-1C563067-19DD-4926-BF7D-3D9B45E7088EQ38081793-9A6D2C72-9963-4149-8121-A64496311B6BQ38107482-5646C85D-C509-48E8-B31E-B6FEF667A7D8Q38155039-C757EAEE-BE61-4835-AE96-04BACE3FDFE2Q38157532-5985E1C1-6C3B-49DE-833B-0A48E8C146FBQ38219408-CA42ADBD-C32D-431C-86C0-928A704C4BC9
P2860
Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Infections in patients with mu ...... dose therapy and novel agents.
@en
Infections in patients with mu ...... dose therapy and novel agents.
@nl
type
label
Infections in patients with mu ...... dose therapy and novel agents.
@en
Infections in patients with mu ...... dose therapy and novel agents.
@nl
prefLabel
Infections in patients with mu ...... dose therapy and novel agents.
@en
Infections in patients with mu ...... dose therapy and novel agents.
@nl
P356
P1476
Infections in patients with mu ...... dose therapy and novel agents.
@en
P304
P356
10.1086/605664
P407
P577
2009-10-01T00:00:00Z